Clearmind Medicine Inc.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address underserved health issues. Its primary efforts center on treatments for alcohol use disorder, including the lead candidate CMND-100, which is in an FDA-approved Phase I/IIa clinical trial, and MEAI, a non-hallucinogenic neuroplastogen targeted at obesity, metabolic disorders, compulsive eating, binge drinking, eating disorders, anxiety, depression, and post-traumatic stress disorder. The company also explores intranasal formulations and collaborations to enhance drug delivery for addiction-related and central nervous system conditions. Clearmind Medicine Inc. maintains an extensive intellectual property portfolio comprising 15 patent families with granted and pending patents across multiple jurisdictions. Founded in 2017 and headquartered in Vancouver, Canada, it operates as a key player in the emerging field of psychedelic medicines for mental health and behavioral disorders.